Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Costas K. Yannakou, Nicholas Murphy, Rosemary Anne Harrup, Craig Wallington-Gates, Magdalena Sobieraj-Teague, M Hasib Sidiqi, Anish Puliyayil, Wojt Janowski, John Reynolds, Andrew Spencer, Hang Quach

Blood (2023) 142 (Supplement 1): 2019.

https://doi.org/10.1182/blood-2023-185944

Published: 2023

Journal Articles

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, Slavisa Ninkovic, Wee-Joo Chng, Andrew Spencer, Peter Mollee, Jay Hocking, Phoebe Joy Ho, Wojt Janowski, Kihyun Kim, Karen Dun, Zoe K McQuilten, Fiona Chen, Hang Quach

Blood (2023) 142 (Supplement 1): 3325.

https://doi.org/10.1182/blood-2023-173896

Published: 2023

Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Nicholas E. Murphy, Hasib Sidiqi, Craig Thomas Wallington-Beddoe, Anish Puliyayil, Costas K. Yannakou, Wojt Janowski, Flora Yuen, Andrew Spencer, Hang Quach

Blood (2021) 138 (Supplement 1): 1671.

https://doi.org/10.1182/blood-2021-151871

Published: 2021

Journal Articles

Inferior Outcomes for Multiple Myeloma (MM) Patients (pts) Harbouring t(11;14) and the Promise of Venetoclax, Real-World Australian Retrospective

Kenneth JC Lim, Dipti Talaulikar, Joanne L C Tan, Joanna Loh, Pratheepan Puvanakumar, James Anton Kuzich, Michelle Ho, Matthew Murphy, Nicole Zeglinas, Sue Morgan, Michael S.Y. Low, David Routledge, Andrew B M Lim, Simon D. Gibbs, Slavisa Ninkovic

Blood (2021) 138 (Supplement 1): 4752.

https://doi.org/10.1182/blood-2021-145508

Published: 2021

Journal Articles

Assessing the Immune Tumour Microenvironment (iTME) Using Multiplex Immunoflourescence Histochemistry (mIHC) Demonstrates Close Proximity of Cytotoxic T-Cells to Plasma Cells (PC) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Slavisa Ninkovic, Louise E. Purton, Simon J Harrison, Hang Quach

Blood (2021) 138 (Supplement 1): 4705.

https://doi.org/10.1182/blood-2021-150471

Published: 2021

Journal Articles

Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone

Slavisa Ninkovic, MBBS FRACP FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Lenny Straszkowski, BSci Hons, Giulia Quattrocchi, Wee-Joo Chng, MBBS, PhD, Louise E Purton, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD

Blood (2019) 134 (Supplement_1): 4376.

https://doi.org/10.1182/blood-2019-128190

Published: 2019

Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Hang Quach, MDFRACP,FRCPA,MBBS, Simon J. Harrison, MBBS,MRCP,FRCPath,FRACP,PhD, Slavisa Ninkovic, MBBS FRACP FRCPA, Jane Estell, MBBS FRACP, Noemi Horvath, MBBS FRACP FRCPA, Nick Murphy, MBBS FRACP FRCPA, Richard Eek, MBCHB, Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rajeev Rajagopal, Akash Kalro, MD, Robyn Hemme, Belinda Butcher, BSc(Hons) MBiostat PhDCMPP AStat, Tracey Gerber, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Brian GM Durie, MD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP

Blood (2018) 132 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2018-99-111434

Published: 2018

Journal Articles

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Elisabeth Schorb, MD, Chris P Fox, Benjamin Kasenda, MDPhD, Teresa Calimeri, MDPhD, Kim Linton, MBChB PhD, Jeffery Smith, MBChB BMedSci MRCP FRCPath, Slavisa Ninkovic, MBBS FRACP FRCPA, Deborah Yallop, MBBS FRCP FRCPath PhD, Hans-Guido Holl, MD, Alberto Fabbri, MD, Thomas E C Cummin, MRCP MBBCh BSc, Gerald Illerhaus, MD, Kate Cwynarski, PhDMD, Andrés J M Ferreri, MD

Blood (2017) 130 (Supplement 1): 376.

https://doi.org/10.1182/blood.V130.Suppl_1.376.376

Published: 2017

Journal Articles

Use of Bortezomib-Containing Regimens in the Frontline Treatment of Patients with Plasmablastic Lymphoma: A Multicenter Retrospective Analysis

Thomas Guerrero, MD, Michele Bibas, MD, Franco Baldini, MD, Guillaume Cartron, Kate Cwynarski, MD, Daan Dierickx, MD PhD, Frederick Lansigan, MD, Yevgeniy A Linnik, MD, Renzo Mogollon, MD, Jose Tomas Navarro, MD PhD, Slavisa Ninkovic, MBBS FRACP FRCPA, Adam J Olszewski, MD, John L. Reagan, MD, Emmanuelle Tchernonog, MD, Thomas Tousseyn, MD PhD, Jorge J. Castillo, MD

Blood (2017) 130 (Supplement 1): 1580.

https://doi.org/10.1182/blood.V130.Suppl_1.1580.1580

Published: 2017

NARROW

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Inferior Outcomes for Multiple Myeloma (MM) Patients (pts) Harbouring t(11;14) and the Promise of Venetoclax, Real-World Australian Retrospective

Assessing the Immune Tumour Microenvironment (iTME) Using Multiplex Immunoflourescence Histochemistry (mIHC) Demonstrates Close Proximity of Cytotoxic T-Cells to Plasma Cells (PC) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Use of Bortezomib-Containing Regimens in the Frontline Treatment of Patients with Plasmablastic Lymphoma: A Multicenter Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only